Evidence map›Paper›PMID 36098742›Full record

ArticleAging2022

Realgar (As

Zonghong Li, Ruiming Zhang, Xuewei Yin, Nana Li, Siyuan Cui, Teng Wang, Xing Tan, Mingyue Shen, Yun Guo, Jinxin Wang and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Mangiferin Ameliorates CClJournal of inflammation research · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Zonghong LiFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Ruiming ZhangDepartment of Hematology, Linyi Hospital of Traditional Chinese Medicine, Linyi 276002, Shandong Province, China.
Xuewei YinFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Nana LiShanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
Siyuan CuiDepartment of Hematology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Teng WangFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Xing TanFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Mingyue ShenCollege of Pharmacy, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Yun GuoCenter for Reproductive Medicine, Cheeloo College of Medicine, Shandong University, Jinan 250000, Shandong Province, China.
Jinxin WangDepartment of Hematology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Dadong GuoShandong Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases, Shandong Academy of Eye Disease Prevention and Therapy, Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Ruirong XuDepartment of Hematology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China.
Shandong University of Traditional Chinese Medicine · CNLinyi City Chinese Medicine Hospital · CNShandong Shierming Eye Hospital · CNShandong University · CNShanghai University of Traditional Chinese Medicine · CNShanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is a specific subtype of acute myelogenous leukemia (AML) characterized by the proliferation of abnormal promyelocytes. Realgar, a Chinese medicine containing arsenic, can be taken orally. Traditional Chinese medicine physicians have employed realgar to treat APL for over a thousand years. Therefore, realgar may be a promising candidate for the treatment of APL. Nevertheless, the underlying mechanism behind realgar therapy is largely unclear. The present study aimed to investigate the effect of realgar on cell death in the APL cell line (NB4)

Indexed as

ArsenicLeukemia, Promyelocytic, AcuteAdenosine TriphosphateApoptosisApoptosis Inducing FactorArsenicalsbcl-2-Associated X ProteinCell DeathCell Line, TumorCytochromes cHumansMedicine, Chinese TraditionalProto-Oncogene Proteins c-bcl-2RNA, MessengerSignal TransductionSulfidesAdenosine TriphosphateApoptosis Inducing FactorArsenicArsenicalsarsenic disulfidebcl-2-Associated X ProteinBCL2 protein, humanCytochromes cProto-Oncogene Proteins c-bcl-2RNA, MessengerSulfidesAIFAPLBaxBcl-2Cyt-Crealgar

Identifiers

PMID36098742
PMCPMC9512515
OpenAlexW4295510638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.